ADMA (ADMA Biologics) Institutional Ownership: 100.46% (As of Jul. 07, 2026)


ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $9.21
GF Value $18.03
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Institutional Ownership?

ADMA Biologics ADMA +0.55% 64 Institutional Ownership is 100.46% as of Jul. 07, 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.03 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ADMA Biologics's institutional ownership is 100.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ADMA Biologics's Insider Ownership is 2.10%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ADMA Biologics's Float Percentage Of Total Shares Outstanding is 81.78%.

ADMA Biologics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Institutional Ownership Chart

ADMA Biologics Historical Data

The historical data trend for ADMA Biologics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 69.92 69.57 70.31 66.92 66.99 67.23 62.39 65.37 63.59 64.44
ADMA
64GF Score
ADMA Biologics Inc ADMA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADMA Biologics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 100.46% mean?
ADMA Biologics (ADMA) has a Institutional Ownership of 100.46% as of Jul. 07, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ADMA Biologics and its competitors.
Is ADMA Biologics' Institutional Ownership too high?
ADMA Biologics' current Institutional Ownership is 100.46%. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Institutional Ownership compare to ZLAB and HRMY?
ADMA Biologics' Institutional Ownership of 100.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Institutional Ownership is 100.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.03, compared to a current price of $9.21 — trading 48.9% below its estimated fair value. The current Institutional Ownership is 100.46%. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Institutional Ownership is 100.46% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $9.21 is trading 48.9% below its estimated GF Value™ of $18.03. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Institutional Ownership: 100.46%
  • GF Value™: $18.03 vs. price of $9.21 (48.9% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.21
Price
$18.03
GF Value